PT3598971T - ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina - Google Patents
¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinureninaInfo
- Publication number
- PT3598971T PT3598971T PT191963669T PT19196366T PT3598971T PT 3598971 T PT3598971 T PT 3598971T PT 191963669 T PT191963669 T PT 191963669T PT 19196366 T PT19196366 T PT 19196366T PT 3598971 T PT3598971 T PT 3598971T
- Authority
- PT
- Portugal
- Prior art keywords
- chlorokynurenine
- dosage forms
- therapeutic uses
- therapeutic
- dosage
- Prior art date
Links
- HQLHZNDJQSRKDT-QMMMGPOBSA-N (2s)-2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=C(Cl)C=C1N HQLHZNDJQSRKDT-QMMMGPOBSA-N 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
- Cosmetics (AREA)
- Lubricants (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361849191P | 2013-01-22 | 2013-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3598971T true PT3598971T (pt) | 2024-06-20 |
Family
ID=51228003
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT171700792T PT3228313T (pt) | 2013-01-22 | 2014-01-22 | Formas de dosagem e utilizações terapêuticas de l-4-cloroquinurenina |
| PT147435705T PT2948140T (pt) | 2013-01-22 | 2014-01-22 | Formas de dosagem e utilizações terapêuticas de l-4-cloroquinurenina |
| PT191963669T PT3598971T (pt) | 2013-01-22 | 2014-01-22 | ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT171700792T PT3228313T (pt) | 2013-01-22 | 2014-01-22 | Formas de dosagem e utilizações terapêuticas de l-4-cloroquinurenina |
| PT147435705T PT2948140T (pt) | 2013-01-22 | 2014-01-22 | Formas de dosagem e utilizações terapêuticas de l-4-cloroquinurenina |
Country Status (22)
| Country | Link |
|---|---|
| US (7) | US9993450B2 (pt) |
| EP (4) | EP4385563A3 (pt) |
| JP (5) | JP6436913B2 (pt) |
| KR (5) | KR102257284B1 (pt) |
| CN (4) | CN113116877A (pt) |
| AU (4) | AU2014209466B2 (pt) |
| BR (1) | BR112015017535A2 (pt) |
| CA (3) | CA3128321C (pt) |
| CY (1) | CY1122403T1 (pt) |
| DK (3) | DK3598971T3 (pt) |
| ES (3) | ES2635353T3 (pt) |
| HK (1) | HK1217170A1 (pt) |
| HR (2) | HRP20240812T1 (pt) |
| HU (1) | HUE067381T2 (pt) |
| IL (3) | IL291831A (pt) |
| MX (2) | MX2015009277A (pt) |
| PL (2) | PL3598971T3 (pt) |
| PT (3) | PT3228313T (pt) |
| RS (1) | RS59687B1 (pt) |
| SI (2) | SI3228313T1 (pt) |
| WO (1) | WO2014116739A1 (pt) |
| ZA (2) | ZA201505569B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6436913B2 (ja) | 2013-01-22 | 2018-12-12 | ヴィスタゲン セラピューティクス、インコーポレイテッド | Ｌ−４−クロロキヌレニンの剤形及び治療的使用 |
| AU2016268153B2 (en) * | 2015-05-22 | 2021-08-12 | Vistagen Therapeutics, Inc. | Therapeutic uses of L-4-chlorokynurenine |
| WO2017044516A1 (en) * | 2015-09-08 | 2017-03-16 | Cephalon, Inc. | Prodrugs of chlorokynurenines |
| CN118026866A (zh) | 2018-02-09 | 2024-05-14 | 维斯塔津治疗公司 | 4-氯代犬尿氨酸及中间体的合成 |
| CN109223785A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用 |
| WO2022082100A1 (en) * | 2020-10-16 | 2022-04-21 | Vistagen Therapeutics, Inc. | Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5086072A (en) * | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| US5360814A (en) | 1991-02-28 | 1994-11-01 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5484814A (en) | 1991-02-28 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| WO2003015713A2 (en) | 2001-08-20 | 2003-02-27 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
| WO2004022069A1 (en) | 2002-09-06 | 2004-03-18 | Durect Corporation | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| BRPI0709984A2 (pt) | 2006-04-12 | 2011-08-02 | Probiodrug Ag | inibidores de enzima |
| EP1903028A1 (en) * | 2006-09-22 | 2008-03-26 | Werner Tschollar | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects |
| CA2606658A1 (en) | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
| WO2009135091A1 (en) * | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
| WO2010022300A1 (en) * | 2008-08-21 | 2010-02-25 | Forest Laboratories Holdings Limited | Methods for treating neuropathic pain |
| EP2421519B1 (en) | 2009-04-23 | 2016-11-02 | Universität Zürich | Blockers of nmda receptor for the treatment of sickle cell anemia |
| WO2010147938A2 (en) * | 2009-06-17 | 2010-12-23 | Targacept, Inc. | Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands |
| CN104777314B (zh) | 2009-08-12 | 2017-01-04 | 福满代谢组技术有限公司 | 抑郁症的生物标记物、抑郁症的生物标记物的测定方法、计算机程序及记录介质 |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| EP2338873A1 (en) * | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
| DK2582366T3 (en) * | 2010-06-15 | 2015-12-07 | Gruenenthal Gmbh | A pharmaceutical combination for the treatment of pain. |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| JP6436913B2 (ja) | 2013-01-22 | 2018-12-12 | ヴィスタゲン セラピューティクス、インコーポレイテッド | Ｌ−４−クロロキヌレニンの剤形及び治療的使用 |
| CN105164096A (zh) | 2013-03-14 | 2015-12-16 | 维斯塔津治疗公司 | 手性犬尿氨酸化合物和中间体的合成 |
| BR112016009443A8 (pt) | 2013-10-28 | 2020-03-24 | Naurex Inc | moduladores do receptor de nmda, pró-drogas e seus sais |
| AU2016268153B2 (en) | 2015-05-22 | 2021-08-12 | Vistagen Therapeutics, Inc. | Therapeutic uses of L-4-chlorokynurenine |
-
2014
- 2014-01-22 JP JP2015553921A patent/JP6436913B2/ja active Active
- 2014-01-22 KR KR1020157022405A patent/KR102257284B1/ko active IP Right Grant
- 2014-01-22 KR KR1020217039478A patent/KR20210149905A/ko not_active Application Discontinuation
- 2014-01-22 DK DK19196366.9T patent/DK3598971T3/da active
- 2014-01-22 CA CA3128321A patent/CA3128321C/en active Active
- 2014-01-22 EP EP24164414.5A patent/EP4385563A3/en active Pending
- 2014-01-22 RS RS20191519A patent/RS59687B1/sr unknown
- 2014-01-22 EP EP19196366.9A patent/EP3598971B1/en active Active
- 2014-01-22 DK DK17170079T patent/DK3228313T3/da active
- 2014-01-22 KR KR1020227044517A patent/KR20230003410A/ko not_active Application Discontinuation
- 2014-01-22 PL PL19196366.9T patent/PL3598971T3/pl unknown
- 2014-01-22 PT PT171700792T patent/PT3228313T/pt unknown
- 2014-01-22 EP EP17170079.2A patent/EP3228313B1/en active Active
- 2014-01-22 HU HUE19196366A patent/HUE067381T2/hu unknown
- 2014-01-22 ES ES14743570.5T patent/ES2635353T3/es active Active
- 2014-01-22 WO PCT/US2014/012598 patent/WO2014116739A1/en active Application Filing
- 2014-01-22 CN CN202110384159.8A patent/CN113116877A/zh active Pending
- 2014-01-22 US US14/762,015 patent/US9993450B2/en active Active
- 2014-01-22 KR KR1020237021428A patent/KR20230098711A/ko not_active Application Discontinuation
- 2014-01-22 CN CN202110387961.2A patent/CN112933073A/zh active Pending
- 2014-01-22 HR HRP20240812TT patent/HRP20240812T1/hr unknown
- 2014-01-22 CA CA2898619A patent/CA2898619C/en active Active
- 2014-01-22 KR KR1020217015432A patent/KR102335919B1/ko active IP Right Grant
- 2014-01-22 ES ES17170079T patent/ES2751138T3/es active Active
- 2014-01-22 CN CN202110387953.8A patent/CN113209068A/zh active Pending
- 2014-01-22 MX MX2015009277A patent/MX2015009277A/es active IP Right Grant
- 2014-01-22 SI SI201431410T patent/SI3228313T1/sl unknown
- 2014-01-22 PL PL17170079T patent/PL3228313T3/pl unknown
- 2014-01-22 PT PT147435705T patent/PT2948140T/pt unknown
- 2014-01-22 IL IL291831A patent/IL291831A/en unknown
- 2014-01-22 ES ES19196366T patent/ES2980120T3/es active Active
- 2014-01-22 SI SI201432078T patent/SI3598971T1/sl unknown
- 2014-01-22 DK DK14743570.5T patent/DK2948140T3/en active
- 2014-01-22 AU AU2014209466A patent/AU2014209466B2/en active Active
- 2014-01-22 EP EP14743570.5A patent/EP2948140B1/en active Active
- 2014-01-22 CA CA3216579A patent/CA3216579A1/en active Pending
- 2014-01-22 BR BR112015017535A patent/BR112015017535A2/pt not_active IP Right Cessation
- 2014-01-22 CN CN201480010060.XA patent/CN105073108A/zh active Pending
- 2014-01-22 PT PT191963669T patent/PT3598971T/pt unknown
-
2015
- 2015-07-17 MX MX2020009966A patent/MX2020009966A/es unknown
- 2015-07-22 IL IL240090A patent/IL240090B/en active IP Right Grant
- 2015-08-03 ZA ZA2015/05569A patent/ZA201505569B/en unknown
-
2016
- 2016-02-08 US US15/018,219 patent/US9993453B2/en active Active
- 2016-05-05 HK HK16105132.0A patent/HK1217170A1/zh unknown
- 2016-11-02 ZA ZA2016/07581A patent/ZA201607581B/en unknown
-
2018
- 2018-05-14 US US15/978,855 patent/US10632091B2/en active Active
- 2018-06-08 US US16/003,816 patent/US10980758B2/en active Active
- 2018-06-08 US US16/003,804 patent/US20180369180A1/en not_active Abandoned
- 2018-06-08 US US16/003,793 patent/US10617663B2/en active Active
- 2018-09-13 JP JP2018171786A patent/JP6804497B2/ja active Active
- 2018-10-26 AU AU2018253600A patent/AU2018253600B2/en active Active
-
2019
- 2019-11-27 CY CY20191101244T patent/CY1122403T1/el unknown
- 2019-12-04 HR HRP20192189TT patent/HRP20192189T1/hr unknown
-
2020
- 2020-07-01 AU AU2020204420A patent/AU2020204420A1/en not_active Abandoned
- 2020-07-03 JP JP2020115273A patent/JP7021298B2/ja active Active
- 2020-07-16 IL IL276126A patent/IL276126B/en unknown
-
2022
- 2022-02-03 JP JP2022015622A patent/JP2022070894A/ja active Pending
- 2022-06-21 US US17/845,105 patent/US12036198B2/en active Active
- 2022-08-22 AU AU2022221382A patent/AU2022221382B2/en active Active
-
2024
- 2024-02-27 JP JP2024027330A patent/JP2024069257A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1223246A1 (zh) | 疼痛藥物組合及其用途 | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| HK1254296A1 (zh) | 治療性化合物和其用途 | |
| IL286759A (en) | Therapeutic methods and preparations | |
| HK1220920A1 (zh) | 治療性組合物和其用途 | |
| HK1217092A1 (zh) | 治療性化合物及其用途 | |
| ZA201607581B (en) | Dosage forms and therapeutic uses l-4lchlorokynurenine | |
| GB201308440D0 (en) | Therapeutic | |
| HK1223833A1 (zh) | 藥物劑型 | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| GB201318668D0 (en) | Sonosensitive therapeutic | |
| GB201308753D0 (en) | Compounds and their use in therapy | |
| GB201317804D0 (en) | Therapeutic compounds and their use | |
| GB201316173D0 (en) | Compounds and their therapeutic use | |
| GB201307677D0 (en) | Compounds and their therapeutic use | |
| EP3071207A4 (en) | Libido-enhancing therapeutic and use | |
| GB201320349D0 (en) | New therapeutic use | |
| GB201313182D0 (en) | Therapeutic treatments | |
| GB201313178D0 (en) | Therapeutic treatments | |
| GB201301072D0 (en) | Therapeutic Moisturiser | |
| GB201300778D0 (en) | Therapeutic moisturiser | |
| GB201308217D0 (en) | Compounds and their use in therapy | |
| GB201319255D0 (en) | Therapeutic compositions and methods |